Long‐term outcomes in heart failure with preserved ejection fraction: Predictors of cardiac and non‐cardiac mortality

AIMS Heart failure (HF) with preserved ejection fraction (HFpEF) is associated with cardiovascular (CV) and non-CV events, but long-term risk is poorly studied. We assessed incidence and predictors of the long-term CV and non-CV events. METHODS AND RESULTS Patients presenting with acute HF, EF ≥ 45%, and N-terminal pro-brain natriuretic peptide > 300 ng/L were enrolled in the Karolinska-Rennes study in 2007-11 and were reassessed after 4-8 weeks in a stable state. Long-term follow-up was conducted in 2018. The Fine-Gray sub-distribution hazard regression was used to detect predictors of CV and non-CV deaths, investigated separately from baseline acute presentation (demographic data only) and from the 4-8 week outpatient visit (including echocardiographic data). Of 539 patients enrolled [median age 78 (interquartile range: 72-84) years; 52% female], 397 patients were available for the long-term follow-up. Over a median follow-up time from acute presentation of 5.4 (2.1-7.9) years, 269 (68%) patients died, 128 (47%) from CV and 120 (45%) from non-CV causes. Incidence rates per 1000 patient-years were 62 [95% confidence interval (CI) 52-74] for CV and 58 (95% CI 48-69) for non-CV death. Higher age and coronary artery disease (CAD) were independent predictors of CV death, and anaemia, stroke, kidney disease, and lower body mass index (BMI) and sodium concentrations of non-CV death. From the stable 4-8 week visit, anaemia, CAD, and tricuspid regurgitation (>3.1 m/s) were independent predictors of CV death, and higher age of non-CV death. CONCLUSIONS In patients with acute decompensated HFpEF, over 5 years of follow-up, nearly of patients died, half from CV and the other half from non-CV causes. CAD and tricuspid regurgitation were associated with CV death. Stroke, kidney disease, lower BMI, and lower sodium were associated with non-CV death. Anaemia and higher age were associated with both outcomes.

[1]  G. Sinagra,et al.  [ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: what's new?] , 2022, Giornale italiano di cardiologia.

[2]  J. Daubert,et al.  Predictors of long‐term outcome in heart failure with preserved ejection fraction: a follow‐up from the KaRen study , 2021, ESC heart failure.

[3]  P. Ponikowski,et al.  Cause of Death in Patients With Acute Heart Failure: Insights From RELAX-AHF-2. , 2020, JACC. Heart failure.

[4]  P. Austin,et al.  A review of the use of time‐varying covariates in the Fine‐Gray subdistribution hazard competing risk regression model , 2019, Statistics in medicine.

[5]  M. Emdin,et al.  Noncardiac Versus Cardiac Mortality in Heart Failure With Preserved, Midrange, and Reduced Ejection Fraction , 2019, Journal of the American Heart Association.

[6]  Erwan Donal,et al.  How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). , 2019, European heart journal.

[7]  L. Lund,et al.  Incidence of, Associations With and Prognostic Impact of Worsening Renal Function in Heart Failure With Different Ejection Fraction Categories. , 2019, The American journal of cardiology.

[8]  J. McMurray,et al.  Microvascular Disease in Patients With Diabetes With Heart Failure and Reduced Ejection Versus Preserved Ejection Fraction , 2019, Diabetes Care.

[9]  L. Lund,et al.  Age-dependent differences in clinical phenotype and prognosis in heart failure with mid-range ejection compared with heart failure with reduced or preserved ejection fraction , 2019, Clinical Research in Cardiology.

[10]  L. Lund,et al.  Prevalence of, associations with, and prognostic role of anemia in heart failure across the ejection fraction spectrum. , 2019, International journal of cardiology.

[11]  C. Cuspidi,et al.  Obesity and heart failure with preserved ejection fraction: a paradox or something else? , 2019, Heart Failure Reviews.

[12]  A. Gavazzi,et al.  Prevalence and prognostic impact of non‐cardiac co‐morbidities in heart failure outpatients with preserved and reduced ejection fraction: a community‐based study , 2018, European journal of heart failure.

[13]  L. Lund,et al.  Associations With and Prognostic and Discriminatory Role of N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Versus Mid-range Versus Reduced Ejection Fraction. , 2018, Journal of cardiac failure.

[14]  Akshay S. Desai,et al.  Coronary microvascular dysfunction and future risk of heart failure with preserved ejection fraction , 2018, European heart journal.

[15]  Nicola Orsini,et al.  Utilizing NT-proBNP for Eligibility and Enrichment in Trials in HFpEF, HFmrEF, and HFrEF. , 2018, JACC. Heart failure.

[16]  Roland A Matsouaka,et al.  Heart Failure With Preserved, Borderline, and Reduced Ejection Fraction: 5-Year Outcomes. , 2017, Journal of the American College of Cardiology.

[17]  Sanjiv J. Shah,et al.  Mode of Death in Heart Failure With Preserved Ejection Fraction. , 2017, Journal of the American College of Cardiology.

[18]  G. Lip,et al.  Risk of stroke in chronic heart failure patients with preserved ejection fraction, but without atrial fibrillation: analysis of the CHARM-Preserved and I-Preserve trials , 2016, European heart journal.

[19]  Erwan Donal,et al.  Value of exercise echocardiography in heart failure with preserved ejection fraction: a substudy from the KaRen study. , 2015, European heart journal cardiovascular Imaging.

[20]  L. Lund,et al.  New echocardiographic predictors of clinical outcome in patients presenting with heart failure and a preserved left ventricular ejection fraction: a subanalysis of the Ka (Karolinska) Ren (Rennes) Study , 2015, European journal of heart failure.

[21]  Victor Mor-Avi,et al.  Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. , 2015, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[22]  J. Daubert,et al.  Association between cardiovascular vs. non‐cardiovascular co‐morbidities and outcomes in heart failure with preserved ejection fraction , 2014, European journal of heart failure.

[23]  V. Melenovský,et al.  Implications of coronary artery disease in heart failure with preserved ejection fraction. , 2014, Journal of the American College of Cardiology.

[24]  J. Daubert,et al.  Baseline characteristics of patients with heart failure and preserved ejection fraction included in the Karolinska Rennes (KaRen) study. , 2014, Archives of cardiovascular diseases.

[25]  J. Daubert,et al.  Rationale and design of the Karolinska‐Rennes (KaRen) prospective study of dyssynchrony in heart failure with preserved ejection fraction , 2009, European journal of heart failure.